Evaluations of the urinary excretion of TIMP-2 and IGFBP7 have been proven useful in the detection of AKI and the urinary concentration of the product of TIMP-2 and IGFBP7 [(TIMP-2) × (IGFBP7)] was the first urinary AKI biomarker approved by the United States Food and Drug Administration (51). Here, IGFBP7 is linked to acute kidney injury.